Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02342249 · ClinicalTrials.gov registry record · Phase 2
Study of Acute Uncomplicated Seasonal Influenza A in Adult Subjects
A Phase 2 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 2
- Development phase
- 292
- Enrollment target
NCT02342249: Completed Phase 2 study, sponsored by Janssen Research & Development.
NCT02342249 is a Phase 2 study that has completed, run by Janssen Research & Development. The registered enrollment target is 292 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (120% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02342249, a Phase 2 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 292 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the antiviral effect, as measured by viral titer in nasal secretions in adults with acute uncomplicated seasonal influenza A following administration of VX-787.
Primary Outcome
Area under the curve (AUC) of the log10 nasal viral load is measured by quantitative reverse transcriptase polymerase chain reaction (qRT-PCR).
Interventions
- DRUG Placebo
- DRUG VX-787 300 mg
- DRUG VX-787 600 mg
- DRUG Oseltamivir 75 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 292 participants |
| Start Date | 2014-12-11 |
| Est. Completion | 2016-05-25 |
| Phase | Phase 2 |
What the finished NCT02342249 record still lists
NCT02342249 is an interventional study that assigns participants to a tested intervention. The registered 292 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (120% higher).
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT02342249 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02342249 about?
NCT02342249 is a clinical study titled "Study of Acute Uncomplicated Seasonal Influenza A in Adult Subjects". The purpose of this study is to evaluate the antiviral effect, as measured by viral titer in nasal secretions in adults with acute uncomplicated seasonal influenza A following administration of VX-787.
What is the current status of trial NCT02342249?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 292 participants. The study started on 2014-12-11. Estimated completion is 2016-05-25.
What interventions are being tested in trial NCT02342249?
The interventions under investigation include: Placebo (DRUG), VX-787 300 mg (DRUG), VX-787 600 mg (DRUG), Oseltamivir 75 mg (DRUG).
Who is sponsoring clinical trial NCT02342249?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02342249's enrollment target sits among peer trials
292 191st of 2000 higher than 1,810 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04429542 · 292 participants · Phase 1
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
- NCT05406622 · 292 participants · NA
MOTIV BTK Randomized Controlled Trial
- NCT05757102 · 292 participants · Phase 3
A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma
- NCT06569667 · 292 participants · NA
Using AI and Peer Coaching to Address Racial Disparities Among People Who Use Opioids
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI